Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$1.23
-2.4%
$1.44
$1.17
$4.84
$12.40M0.47509,692 shs51,152 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
+0.80%+3.28%-15.44%-27.17%-50.59%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.8644 of 5 stars
0.03.00.00.02.72.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
$33.26K372.84N/AN/A$0.22 per share5.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
-$6.99M-$0.76N/AN/AN/A-195.35%-162.37%N/A

Latest BFRG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/A-$0.15N/A-$0.15N/A$0.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
N/A
3.97
3.97

Institutional Ownership

CompanyInstitutional Ownership
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
0.96%

Insider Ownership

CompanyInsider Ownership
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
24.72%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bullfrog AI Holdings Inc. stock logo
BFRG
Bullfrog AI
410.08 million7.59 millionNot Optionable

Recent News About These Companies

Analyzing Bullfrog AI (NASDAQ:BFRG) and iRhythm Technologies (NASDAQ:IRTC)
BFRG - Bullfrog AI Holdings Inc News | Morningstar
Can BullFrog AI Continue to Leap Higher?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bullfrog AI stock logo

Bullfrog AI NASDAQ:BFRG

$1.23 -0.03 (-2.38%)
Closing price 04:00 PM Eastern
Extended Trading
$1.21 -0.02 (-1.63%)
As of 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.